drugset / Trial / NCT01369862

Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults

NCT01369862 ↗

Phase 1/2 Completed 80 enrolled AVIR Green Hills Biotechnology AG
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this phase I/II trial is to evaluate safety and tolerability of a single dose of GHB16L2 administered by liquid nasal spray for vaccination against seasonal influenza virus infection. It is also performed to assess immunogenicity and pharmacokinetics (shedding).

Timeline

Start
2011-01
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject GHB16L2 Unknown 7 unknown Intranasal

Indications